{
    "nct_id": "NCT05907954",
    "official_title": "(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma",
    "inclusion_criteria": "* Primary localized uveal melanoma requiring either enucleation or plaque brachytherapy\n* Able to dose orally\n* ECOG Performance status of 0-1\n* No other significant underlying ocular disease\n* Adequate organ function\n* Not pregnant/nursing or planning to become pregnant. Willing to use birth control\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Previous treatment with a Protein Kinase C (PKC) inhibitor\n* Concurrent malignant disease\n* Active HIV infection or Hep B/C\n* Malabsorption disorder\n* Unable to discontinue prohibited medication\n* Impaired cardiac function or clinically significant cardiac disease\n* Any other condition which may interfere with study interpretation or results",
    "miscellaneous_criteria": ""
}